Iridex (IRIX) announced the publication of a peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy in managing both primary and secondary glaucoma over five years. Conducted by Ronald de Crom and colleagues at the University Eye Clinic Maastricht, Netherlands, this research is the first to evaluate outcomes of MicroPulse TLT over such an extended period. The study assessed 165 pre- and post-cataract eyes treated between 2016 and 2019, with 112 eyes completing the five-year follow-up. Treatment was delivered using the Iridex Cyclo G6 Laser in its MicroPulse Mode and the original MicroPulse P3 Delivery Device. Results demonstrated that MicroPulse TLT achieved significant reductions in intraocular pressurer -32.5% on average-while also enabling a significant reduction in IOP-lowering medications with a low rate of complications across a broad range of glaucoma types and severities. Additionally, over the five-year follow-up period, only 38% of eyes required retreatment.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IRIX:
- Iridex CEO Patrick Mercer Joins Board of Directors
- Iridex comments on changing glaucoma reimbursement landscape
- Iridex Leadership Changes and Strategic Appointments
- Iridex Corporation’s Q3 2024 Financial Performance Overview
- IRIX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
